- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BPI-2009H | Conmana®
icotinib is an approved drug
Compound class: Synthetic organic
Comment: Icotinib is a selective, orally available epidermal growth factor receptor tyrosine kinase inhibitor [1-3]. Icotinib is a 'pseudo' INN, that takes the form of an INN, but has not been submitted to the World Health Organisation for ratification.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, Wang F, Kang X, Tan F, Ding L et al.. (2012)
Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
Bioorg. Med. Chem. Lett., 22 (19): 6301-5. [PMID:22959248]
2. Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L, Hu Y, He W, Wang Y, Wang Y. (2012)
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
Lung Cancer, 76 (2): 177-82. [PMID:22112293]
3. Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y, Zhou J. (2011)
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Lung Cancer, 73 (2): 195-202. [PMID:21144613]